CHMP recommends restricted use for two fluroquinolones
This article was originally published in Scrip
Executive Summary
Following the conclusion of two referral procedures, the European Medicine Agency's scientific committee, theCHMP, has recommended that use of two oral fluoroquinolones – moxifloxacin (Bayer's Avelox) and norfloxacin (numerous branded and generic versions) – be restricted.